@article {Gualtieri:2005:1567-2034:471,
title = "Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD): An Update [1]",
journal = "Medicinal Chemistry Reviews - Online",
parent_itemid = "infobike://ben/mcro",
publishercode ="ben",
year = "2005",
volume = "2",
number = "6",
publication date ="2005-12-01T00:00:00",
pages = "471-487",
itemtype = "ARTICLE",
issn = "1567-2034",
url = "https://www.ingentaconnect.com/content/ben/mcro/2005/00000002/00000006/art00003",
doi = "doi:10.2174/156720305775009643",
keyword = "NMDA receptor antagonist, NSAIDs, acetylcholinesterase (AChE) inhibitors, Neuromodulation, AMPA receptor, Aniracetam",
author = "Gualtieri, Fulvio and Guandalini, Luca and Manetti, Dina and Martini, Elisabetta and Romanelli, Maria N.",
abstract = "Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and agerelated pathologies such as MCI and AD. Development of cognition enhancers is still a difficult task because of the complexity of the brain functions, poor predictivity of animal tests and lengthy and expensive clinical trials. Current research is based on several working hypotheses, derived from the progress of knowledge in the neuro-bio-pathology of cognitive processes. Approaches followed to develop cognition enhancing drugs, the results obtained in the past few years (since 2000) and the most promising molecules under study are reviewed.",
}